TGI
FULC icon

TRV GP IV’s Fulcrum Therapeutics FULC Stock Holding History

TRV GP IV’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,343,154
Closed -$8.37M – 3
2024
Q3 		$8.37M Hold
2,343,154
– – 5.16% 3
2024
Q2 		$14.5M Hold
2,343,154
– – 7.18% 3
2024
Q1 		$22.1M Hold
2,343,154
– – 10.72% 3
2023
Q4 		$15.8M Hold
2,343,154
– – 6.43% 3
2023
Q3 		$10.4M Hold
2,343,154
– – 3.92% 3
2023
Q2 		$7.73M Hold
2,343,154
– – 6.99% 3
2023
Q1 		$6.68M Hold
2,343,154
– – 4.77% 3
2022
Q4 		$17.1M Hold
2,343,154
– – 7.25% 4
2022
Q3 		$19M Hold
2,343,154
– – 11.08% 4
2022
Q2 		$11.5M Hold
2,343,154
– – 7.55% 4
2022
Q1 		$55.4M Hold
2,343,154
– – 20.3% 2
2021
Q4 		$41.5M Hold
2,343,154
– – 11.92% 2
2021
Q3 		$66.1M Hold
2,343,154
– – 15% 2
2021
Q2 		$24.6M Hold
2,343,154
– – 11.69% 4
2021
Q1 		$27.6M Hold
2,343,154
– – 10.17% 4
2020
Q4 		$27.4M Hold
2,343,154
– – 8.8% 5
2020
Q3 		$18.6M Hold
2,343,154
– – 6.4% 5
2020
Q2 		$42.9M Hold
2,343,154
– – 19.74% 4
2020
Q1 		$28M Hold
2,343,154
– – 25.58% 3
2019
Q4 		$39M Hold
2,343,154
– – 24.31% 2
2019
Q3 		$15.6M Buy
+2,343,154
New +$25.9M 15.92% 2

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

TRV GP IV's FULC Position: Q4 2024 in Review

TRV GP IV sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 2,343,154 shares — an estimated $8.37M sold.

TRV GP IV first reported a position in FULC in Q3 2019 and held it in 21 quarters. The position peaked at $66.1M in Q3 2021. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • TRV GP IV reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • TRV GP IV sold 2,343,154 Fulcrum Therapeutics shares in Q4 2024, an estimated $8.37M.
  • TRV GP IV first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 21 quarters.
  • TRV GP IV's Fulcrum Therapeutics position peaked at $66.1M in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on TRV GP IV's 13F filing for Q4 2024, filed 13 Feb 2025.